Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Blueprint Medicines to acquire LNG-451 with Lengo Therapeutics acquisition

Nov. 30, 2021

Discovery of the novel BCL6 BTB-specific inhibitor, AP-4-287

Nov. 29, 2021

Merck & Co. synthesizes new LAAO inhibitors

Nov. 29, 2021

Study reports tumors change as patients age

Nov. 26, 2021

Merck, Cancer Research Technology divulge YAP1/TEAD interaction inhibitors

Nov. 26, 2021

New MAP4K1 inhibitors synthesized at Pfizer

Nov. 26, 2021

Adenosine A2A receptor antagonists identified at Adorx Therapeutics

Nov. 26, 2021

Restoration of NXTAR as a novel approach for prostate cancer treatment with enzalutamide

Nov. 25, 2021

Meiji Seika Pharma divulges histamine H4 receptor antagonists

Nov. 25, 2021

New PADI4 inhibitors synthesized at Gilead

Nov. 25, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.